ArticleFrontiers in oncology2025
Contrast-enhanced ultrasound diagnosis and efficacy prediction of primary breast lymphoma: a case report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary breast lymphoma (PBL) is a rare entity, accounting for less than 1% of all breast malignancies. PBL is often difficult to differentiate from other benign and malignant breast tumors. This case report describes the contrast-enhanced ultrasound (CEUS) diagnosis of PBL in a 34-year-old female patient, initially presenting with a left breast lump. CEUS revealed some distinctive features: diffuse hyperenhancement with the "floating vessel" sign. These findings enabled a timely diagnosis. Histopathological analysis confirmed diffuse large B-cell lymphoma. After more than two years of chemotherapy, CEUS revealed significant lesion shrinkage with well-defined margins alongside delayed arrival time, reduced peak intensity, and a decreased area under the curve, collectively indicating a favorable chemotherapeutic response. Eventually, the patient underwent surgery, and pathological examination confirmed the absence of significant lymphoma cells following chemotherapy. This case underscores the value of CEUS in identifying PBL and assessing chemotherapy efficacy through qualitative characterization and quantitative parameters, thereby demonstrating its dual role in both lesion identification and therapeutic monitoring. It also emphasizes the significance of including lymphoma in the differential diagnosis of breast masses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.